Theravance Biopharma (TBPH) Cash & Equivalents (2014 - 2026)

Theravance Biopharma (TBPH) has reported Cash & Equivalents for 13 consecutive years, with $288.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 160.46% year-over-year to $288.1 million; the TTM figure through Mar 2026 stood at $288.1 million (up 160.46% YoY), while the FY2025 annual figure was $167.8 million, up 343.97% from the prior year.
• Cash & Equivalents advanced to $288.1 million in Q1 2026 per TBPH's latest filing, from $167.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $418.5 million in Q3 2022 and bottomed at $23.4 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $146.3 million across 5 years, with a median of $105.6 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 86.74% — and 2025, when it soared 647.6%.
• Theravance Biopharma's Cash & Equivalents stood at $298.2 million in 2022, then slumped by 86.74% to $39.5 million in 2023, then slipped by 4.42% to $37.8 million in 2024, then jumped by 343.97% to $167.8 million in 2025, then surged by 71.69% to $288.1 million in 2026.
• Business Quant data shows TBPH's Cash & Equivalents at $288.1 million in Q1 2026, $167.8 million in Q4 2025, and $174.8 million in Q3 2025.